ストックスクリーナーアプリを入手
3.04
0.65%
-0.02
アフターアワーズ：
3.23
0.19
+6.25%
前日終値:
$3.06
開ける：
$3.06
24時間の取引高:
6,709
Relative Volume:
0.18
時価総額：
$20.26M
収益：
$105.38M
当期純損益:
$17.78M
株価収益率:
-0.6566
EPS:
-4.63
ネットキャッシュフロー:
$-50.48M
1週間 パフォーマンス:
-4.10%
1か月 パフォーマンス:
+8.19%
6か月 パフォーマンス:
-0.65%
1年 パフォーマンス:
-57.30%
1日の値動き範囲:
$3.01
$3.10
1週間の範囲:
$2.98
$3.29
52週間の値動き範囲:
$2.61
$7.8734
Mei Pharma Inc Stock (MEIP) Company Profile
Mei Pharma Inc Stock (MEIP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-03-25 | ダウングレード | Jefferies | Buy → Hold |
| 2022-03-25 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-02-03 | 開始されました | Jefferies | Buy |
| 2020-09-22 | 開始されました | Alliance Global Partners | Buy |
| 2020-05-29 | 開始されました | SunTrust | Buy |
| 2018-12-20 | 開始されました | H.C. Wainwright | Buy |
| 2018-07-27 | アップグレード | Stifel | Hold → Buy |
| 2018-07-13 | 開始されました | SunTrust | Buy |
| 2016-04-18 | 繰り返されました | Wedbush | Neutral |
| 2015-03-23 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2014-12-18 | 繰り返されました | ROTH Capital | Buy |
| 2014-10-16 | 繰り返されました | ROTH Capital | Buy |
| 2014-07-08 | 再開されました | Brean Capital | Buy |
| 2013-10-22 | 繰り返されました | Stifel | Buy |
| 2013-04-15 | 開始されました | Stifel | Buy |
すべてを表示
Mei Pharma Inc (MEIP) 最新ニュース
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
Data Readouts At EHA Congress 2021 (APTO, XFOR, GBT, CRIS…) - RTTNews
Stocks to Watch: MEI Pharma, Hawaiian Electric Industries - MarketWatch
MEI Shares Rise After Entering Asset Purchase Agreement Valued at Up to $62 Million - MarketWatch
MEI Pharma postpones special meeting to vote on Infinity deal until July 23 - MSN
Aardvark Therapeutics, Inc. agreed to acquire rights, title and interest in and to certain assets related to ME-344 from MEI Pharma, Inc. for $62.5 million. - Marketscreener.com
MEIP (MEI Pharma) Free Cash Flow per Share : $-7.57 (TTM As of Jun. 2024) - GuruFocus.com
Post Polycythemia Vera Myelofibrosis Market: Holistic - openPR
Ampio Pharmaceuticals (NYSE:AMPE) Coverage Initiated by Analysts at StockNews.com - Defense World
MEI Pharma stock hits 52-week low at $2.72 amid market challenges - Investing.com India
MEI Pharma stock hits 52-week low at $2.72 amid market challenges By Investing.com - Investing.com South Africa
Acute Myeloid Leukemia Market Trends, Key Drivers, Opportunities, Leading Players And Forecast To 2033 - WhaTech
Histone Deacetylase 2 Industry Forecast (2024-2034) Under Inflation - Apiculture Market: Report ...
Myelodysplastic Syndrome Drugs Market Research Explores Size, Market Competitive Landscape, Business Growth... - WhaTech
Chronic Lymphocytic Leukemia Treatment Market Advancements Highlighted by Comprehensive Analysis, Advanceme... - WhaTech
Follicular Lymphoma Treatment Market Insights Discussed Regarding Size, Trends, and Overview Report 2024-2033 - WhaTech
MEI Pharma reviews strategic options amid fiscal changes - Investing.com India
MEI Pharma confirms continuation of evaluation of strategic alternatives - TipRanks
MEI Pharma Reports Fiscal Year End 2024 Cash Position - The Bakersfield Californian
Expanding the Bispecific Antibody Market from CAR-Ts to Drive Follicular Lymphoma's Future | DelveInsight - PR Newswire UK
LPL Financial (NASDAQ:LPLA) Research Coverage Started at Wells Fargo & Company - Defense World
Los Angeles Capital Management LLC Reduces Stake in Martin Marietta Materials, Inc. (NYSE:MLM) - Defense World
Histone Deacetylase Inhibitors Report 2024, Industry Analysis And Overview By 2033 - WhaTech
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry - openPR
MEIP (MEI Pharma) Dividends per Share : $0.00 (TTM As of Mar. 2024) - GuruFocus.com
Rx Rundown: Vantive, Gilead Sciences, Halda Therapeutics and more - MM+M Online
MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives - StockTitan
StockNews.com Initiates Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
GreenWood Investors First Half 2024 Letter - Seeking Alpha
MEI Pharma (MEIP) – Research Analysts’ Recent Ratings Updates - Defense World
Game-Changing BCL-2 Inhibitors Set to Revolutionize Cancer Treatment Market | DelveInsight - GlobeNewswire
MEI Pharma announces executive departures and strategic shifts - Investing.com
MEI Pharma announces executive departures and strategic shifts By Investing.com - Investing.com Canada
MEI Pharma Explores Strategic Shifts, Leadership Changes - TipRanks
Non-Hodgkin's Lymphoma Therapeutics Market to Reach USD 18.6 Billion by 2034: Fuelled by New Drugs and Targeted Therapies | Latest Report by TMR - PR Newswire
MEI Pharma Explores Strategic Options, Halts Drug Development - TipRanks
Acadian Asset Management LLC Sells 13,658 Shares of MEI Pharma, Inc. (NASDAQ:MEIP) - Defense World
Biopharma Layoff Tracker 2024: Anokion, GlycoMimetics, Relay and More Cut Staff - BioSpace
MEI Pharma (NASDAQ:MEIP) Receives New Coverage from Analysts at StockNews.com - Defense World
StockNews.com Initiates Coverage on Perficient (NASDAQ:PRFT) - Defense World
MEI Pharma (NASDAQ:MEIP) Downgraded by Brookline Capital Management - Defense World
State Board of Administration of Florida Retirement System Increases Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Blair William & Co. IL Takes Position in BRC Inc. (NYSE:BRCC) - Defense World
Avantax Advisory Services Inc. Buys Shares of 8,840 Dimensional World ex U.S. Core Equity 2 ETF (NYSEARCA:DFAX) - Defense World
MEI Pharma (NASDAQ:MEIP) Downgraded by Laidlaw - Defense World
Does MEI Pharma Inc (NASDAQ: MEIP) Still Need To Convince Analysts? - Stocks Register
Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1 - Marketscreener.com
MEI Pharma stock downgraded amid strategic review and shutdown risk By Investing.com - Investing.com Canada
MEI Pharma initiates strategic review and layoffs By Investing.com - Investing.com Australia
MEI Pharma initiates strategic review and layoffs - Investing.com
Mei Pharma Inc (MEIP) 財務データ
収益
当期純利益
現金流量
EPS
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):